Professor Sir Martin Landray
- EMPA-KIDNEY: the study of heart and kidney protection with empagliflozin
- HPS2 -THRIVE: Treatment of HDL to Reduce the Incidence of Vascular Events
- HPS3 / TIMI 55 - REVEAL : Randomised Evaluation of the Effects of Anacetrapib through Lipid-modification
- Renal Studies Group
- Research Regulation
- SHARP: Study of Heart and Renal Protection
- Trials Methodology
- Big Data Institute (BDI)
Professor of Medicine and Epidemiology
- MRC Investigator, MRC Population Health Research Unit
- Chief Executive Officer, Protas
- Honorary Consultant Physician, Oxford University Hospitals NHS Foundation Trust
Martin Landray is Professor of Medicine & Epidemiology at Oxford Population Health and Deputy Director of the University of Oxford's Big Data Institute.
Professor Landray’s work seeks to further understanding of the determinants of common diseases chiefly through the design, conduct and analysis of efficient, large-scale clinical trials. He has led a series of major clinical trials, chiefly of treatments for cardiovascular and kidney disease. The results of these trials have influenced regulatory drug approvals, clinical guidelines, and prescribing practice to the benefit of patients. Since March 2020, he has co-led the RECOVERY trial, the world’s largest trial of potential treatments for COVID-19, publishing definitive results for multiple treatments, including the discovery that dexamethasone reduces mortality for the sickest patients.
He leads Protas, a not-for-profit organisation focused on smarter randomised trials for better public health. He leads the Good Clinical Trials Collaborative in the development, promotion and adoption of guidelines for randomised controlled trials, supported by Wellcome and the Bill & Melinda Gates Foundation. In 2021, he was appointed to the Pandemic Preparedness Partnership leading to the publication of the G7 100 Days Mission to Respond to Future Pandemic Threats which recommended significant regulatory improvements to facilitate the rapid generation of relevant and robust results from innovative randomised controlled trials.
Professor Landray completed medical training at the University of Birmingham (UK) and specialist training in Clinical Pharmacology & Therapeutics and General Internal Medicine at the University of Birmingham. He continues to practise clinical medicine as an Honorary Consultant Physician in the Department of Cardiology at Oxford University Hospitals NHS Foundation Trust. In 2021 he was elected Fellow of the Academy of Medical Sciences and was knighted for services to public health and science.
Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease
Mayne K. et al, (2023), Journal of the American Society of Nephrology
Methylprednisolone, intravenous immunoglobulin, tocilizimab or anakinra for children with Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS CoV-2 (PIMS-TS, MIS-C) – report from a randomised, controlled, open-label, platform trial
LANDRAY M. et al, (2023), Lancet Child and Adolescent Health
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2023), Lancet Diabetes Endocrinol
Correction: Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments.
Cake C. et al, (2023), Trials, 24
Delivering trials in the NHS: more than worth it.
Haynes R. et al, (2023), Clin Med (Lond), 23, 525 - 526
IN the News
Lectures, webcasts and interviews
RECOVERY - reflections and future directions
British Pharmacological Society, September 2021
Big Trials, Big Data, Big Potential: population health research in the 21st century
Inaugural Lecture, University of Oxford, November 2015